Bristol-Myers Squibb Co [NYSE: BMY] closed the trading session at $15290000.0 on 2025-06-20. The day’s price range saw the stock hit a low of $46.72, while the highest price level was $47.39.
The stocks have a year to date performance of 14.38 percent and weekly performance of -7.56 percent. The stock has been moved at -16.13 percent over the last six months. The stock has performed -2.11 percent around the most recent 30 days and changed -22.44 percent over the most recent 3-months.
If compared to the average trading volume of 15.29M shares, BMY reached to a volume of 47287216 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Bristol-Myers Squibb Co [BMY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $55.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.64. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Bristol-Myers Squibb Co shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 22, 2025. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Neutral. The new note on the price target was released on April 22, 2025, representing the official price target for Bristol-Myers Squibb Co stock. Previously, the target price had yet another raise to $70, while Jefferies analysts kept a Buy rating on BMY stock.
The Price to Book ratio for the last quarter was 5.48, with the Price to Cash per share for the same quarter was set at 5.79. Price to Free Cash Flow for BMY in the course of the last twelve months was 7.29 with Quick ratio for the last quarter at 1.17.
BMY stock trade performance evaluation
Bristol-Myers Squibb Co [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.56. With this latest performance, BMY shares dropped by -2.11% in over the last four-week period, additionally sinking by -16.13% over the last 6 months – not to mention a drop of -17.15% in the past year of trading.
Bristol-Myers Squibb Co [BMY]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Co [BMY] shares currently have an operating margin of 22.93% and a Gross Margin at 59.16%. Bristol-Myers Squibb Co’s Net Margin is presently recorded at 11.38%.
Return on Equity for this stock inclined to 5.66%, with Return on Assets sitting at 5.66%.
Earnings per share (EPS) analysis for Bristol-Myers Squibb Co [BMY] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Co go to 72.80%.
Bristol-Myers Squibb Co [BMY]: Institutional Ownership
There are presently around $82.23%, or 82.29%% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 186.57 million shares, which is approximately 9.2043%. BLACKROCK INC., holding 158.66 million shares of the stock with an approximate value of $$6.59 billion in BMY stocks shares; and BLACKROCK INC., currently with $$3.8 billion in BMY stock with ownership which is approximately 4.5114%.
